Surrozen (SRZN) Net Cash Flow (2020 - 2026)
Surrozen (SRZN) posted quarterly Net Cash Flow of $17.7 million for Q1 2026, down 73.67% year-over-year from $67.1 million in Q1 2025, and up 124.17% quarter-over-quarter from $7.9 million in Q4 2025.
Surrozen (SRZN) Net Cash Flow (2020 - 2026) Analysis & Trends
Surrozen's Net Cash Flow history runs 7 years deep, the most recent figure standing at $17.7 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 73.67% year-over-year to $17.7 million; the TTM figure through Mar 2026 stood at $5.3 million (down 92.93% YoY), while the FY2025 annual figure was $54.7 million, up 3871.03% from the prior year.
- Net Cash Flow for Q1 2026 stood at $17.7 million, up from $7.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $67.1 million in Q1 2025, with the low at -$18.8 million in Q1 2022.
- The 5-year median for Net Cash Flow is $2.5 million (2022), against an average of $4.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 383.36% in 2024, then soared 866.37% in 2025.
- Surrozen's Net Cash Flow stood at -$836000.0 in 2022, then surged by 380.02% to $2.3 million in 2023, then jumped by 52.58% to $3.6 million in 2024, then jumped by 120.55% to $7.9 million in 2025, then soared by 124.17% to $17.7 million in 2026.
- Business Quant data shows SRZN's Net Cash Flow at $17.7 million in Q1 2026, $7.9 million in Q4 2025, and -$9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -4.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.92 Mn |
| Jun 30, 2026 | -4.92 Mn |
| Mar 31, 2026 | 17.66 Mn |
| Mar 31, 2026 | 17.66 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Jun 30, 2025 | -11.26 Mn |
| Jun 30, 2025 | -11.26 Mn |
| Mar 31, 2025 | 67.08 Mn |
| Mar 31, 2025 | 67.08 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Mar 31, 2024 | -8.75 Mn |